Tue Oct 01 01:38:59 UTC 2024: ## RxSight Insider Sells Shares, Institutional Investors Show Interest
**RxSight, Inc. (NASDAQ: RXST)** saw insider Ilya Goldshleger sell 3,105 shares of the company’s stock on September 26th at an average price of $49.29, totaling $153,045.45. Following the transaction, Goldshleger directly owns 42,246 shares, valued at $2,082,305.34.
Meanwhile, institutional investors have been active in adjusting their holdings of RxSight. Several funds, including Amalgamated Bank, Crossmark Global Holdings Inc., RiverPark Advisors LLC, CWM LLC, and Arizona State Retirement System, have increased their positions in the company during the second quarter.
Analysts have also weighed in on RXST, with Stifel Nicolaus, Needham & Company LLC, Oppenheimer, Wells Fargo & Company, and BTIG Research recently adjusting their price targets and ratings. Currently, seven analysts rate the stock with a “buy” rating, resulting in an average rating of “Buy” and an average target price of $60.14, according to MarketBeat data.
RxSight, a commercial-stage medical device company, specializes in the development and sale of light adjustable intraocular lenses (LAL) used in cataract surgery. Their RxSight system allows doctors to customize visual acuity for patients after cataract surgery.
First Piper 